{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:08:21Z","timestamp":1788433701093,"version":"build-2803163510"},"reference-count":22,"publisher":"American Society of Hematology","issue":"2","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,23]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite improvements in treatment of mantle cell lymphoma (MCL), most patients eventually relapse. In this multicenter phase 1b\/2 trial, we evaluated safety and efficacy of minimal residual disease (MRD)\u2013driven venetoclax, lenalidomide, and rituximab (venetoclax-R2) in relapsed\/refractory (R\/R) MCL and explored the feasibility of stopping treatment in molecular remission. The primary end point was overall response rate (ORR) at 6\u00a0months. After dose escalation, the recommended phase 2 dose was lenalidomide 20\u00a0mg daily, days 1 to 21; venetoclax 600\u00a0mg daily after ramp-up; and rituximab 375\u00a0mg\/m2 weekly for 4\u00a0weeks, then every 8\u00a0weeks. MRD monitoring by RQ-PCR was performed every 3\u00a0months. When MRD-negativity in the blood was reached, treatment was continued for another 3\u00a0months; if MRD-negativity was then confirmed, treatment was stopped. In total, 59 patients were enrolled, with a median age of 73 years. At 6\u00a0months, the ORR was 63% (29 complete remission [CR], 8 partial remission [PR]), and 40% (4 CR, 2 PR) for patients previously failing a Bruton tyrosine kinase (BTK) inhibitor. Median progression-free survival (PFS) was 21\u00a0months, with median overall survival of 31\u00a0months. TP53 mutation was associated with inferior PFS (P\u00a0&amp;lt; .01). Overall, 28 patients (48%) discontinued treatment in molecular remission, and 25 remain MRD negative after a median of 17.4\u00a0months. Hematological toxicity was frequent, with 52 of 59 (88%) patients with G3-4 neutropenia and 21 of 59 (36%) patients with G3-4 thrombocytopenia. To conclude, MRD-driven venetoclax-R2 is feasible and tolerable and shows efficacy in R\/R MCL, also after BTK inhibitor failure. This trial was registered at www.ClinicalTrials.gov as #NCT03505944.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011920","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T21:27:13Z","timestamp":1703021233000},"page":"407-415","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial"],"prefix":"10.1182","volume":"8","author":[{"given":"Mats","family":"Jerkeman","sequence":"first","affiliation":[{"name":"1Department of Oncology, Institute of Clinical Sciences, Lund University and Skane University Hospital SE22185, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Kolstad","sequence":"additional","affiliation":[{"name":"2Department of Oncology, Innlandet Hospital, Brumunddal, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3873-1741","authenticated-orcid":false,"given":"Martin","family":"Hutchings","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Pasanen","sequence":"additional","affiliation":[{"name":"4Department of Oncology, Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6378-5381","authenticated-orcid":false,"given":"Leo","family":"Meriranta","sequence":"additional","affiliation":[{"name":"4Department of Oncology, Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-5242","authenticated-orcid":false,"given":"Carsten Utoft","family":"Niemann","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7249-2196","authenticated-orcid":false,"given":"Rasmus Rask","family":"Kragh J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Aalborg University Hospital, Aalborg, Denmark"},{"name":"6Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4406-380X","authenticated-orcid":false,"given":"Tarec Christoffer","family":"El-Galaly","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Aalborg University Hospital, Aalborg, Denmark"},{"name":"6Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0024-0093","authenticated-orcid":false,"given":"Jon","family":"Riise","sequence":"additional","affiliation":[{"name":"7Department of Oncology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8265-511X","authenticated-orcid":false,"given":"Sirpa","family":"Lepp\u00e4","sequence":"additional","affiliation":[{"name":"4Department of Oncology, Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob Haaber","family":"Christensen","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Sonnevi","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Karolinska University Hospital, Stockholm, Sweden"},{"name":"10Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone Bredo","family":"Pedersen","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin Fahl","family":"Wader","sequence":"additional","affiliation":[{"name":"11Department of Oncology, St Olav University Hospital, Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6158-3041","authenticated-orcid":false,"given":"Ingrid","family":"Glimelius","sequence":"additional","affiliation":[{"name":"12Department of Immunology, Genetics and Pathology, Unit of Cancer Precision Medicine, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"issue":"10020","key":"2024012221513877000_bib1","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"2024012221513877000_bib2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-020-01013-3","article-title":"Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study","volume":"35","author":"Visco","year":"2021","journal-title":"Leukemia"},{"issue":"10121","key":"2024012221513877000_bib3","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"2024012221513877000_bib4","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam","year":"2021","journal-title":"Blood Adv"},{"issue":"24","key":"2024012221513877000_bib5","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1200\/JCO.23.00562","article-title":"Pirtobrutinib in covalent BTK-inhibitor pre-treated mantle cell lymphoma","volume":"41","author":"Wang","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"2024012221513877000_bib6","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024012221513877000_bib7","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1097\/HS9.0000000000000510","article-title":"Detailed long-term follow-up of patients who relapsed after the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3","volume":"5","author":"Eskelund","year":"2021","journal-title":"Hemasphere"},{"issue":"27","key":"2024012221513877000_bib8","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024012221513877000_bib9","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"issue":"7","key":"2024012221513877000_bib10","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in\u00a0vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2024012221513877000_bib11","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"issue":"7","key":"2024012221513877000_bib12","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.2020008727","article-title":"Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial","volume":"137","author":"Le Gouill","year":"2021","journal-title":"Blood"},{"issue":"13","key":"2024012221513877000_bib13","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"2024012221513877000_bib14","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1182\/bloodadvances.2023009992","article-title":"Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma","volume":"7","author":"Phillips","year":"2023","journal-title":"Blood Adv"},{"issue":"26","key":"2024012221513877000_bib15","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","article-title":"Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma","volume":"27","author":"Andersen","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"2024012221513877000_bib16","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2024012221513877000_bib17","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1111\/bjh.17063","article-title":"A\u00a0high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma","volume":"191","author":"Obr","year":"2020","journal-title":"Br J Haematol"},{"issue":"6","key":"2024012221513877000_bib18","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","article-title":"KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study","volume":"105","author":"Ferrero","year":"2020","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2024012221513877000_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2022-163018","article-title":"Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the Randomized Triangle Trial by the European MCL Network","volume":"140","author":"Dreyling","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2024012221513877000_bib20","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy","volume":"104","author":"Eyre","year":"2019","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2024012221513877000_bib21","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood-2022-157777","article-title":"Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma","volume":"140","author":"Phillips","year":"2022","journal-title":"Blood"},{"issue":"10306","key":"2024012221513877000_bib22","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2024013955","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/2\/407\/2210540\/blooda_adv-2023-011920-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/2\/407\/2210540\/blooda_adv-2023-011920-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T21:51:55Z","timestamp":1705960315000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/2\/407\/506672\/MRD-driven-treatment-with-venetoclax-R2-in-mantle"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011920","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/bloodadvances.2024013955","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,12]]}}}